Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the completion of a $115 million Series D financing that included the conversion of issued convertible notes previously purchased by existing investors.

Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有肾脏，心血管和代谢疾病的患者开发新型小分子精密药物，今天宣布完成1.15亿美元的D系列融资，其中包括转换先前由现有投资者购买的已发行可转换票据。

The Series D financing was co-led by investors Frazier Life Sciences and Deep Track Capital. Janus Henderson Investors and Logos Capital also participated. Existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures, as well as other existing leading healthcare investors.Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.

D系列融资由投资者Frazier Life Sciences和Deep Track Capital共同牵头。Janus Henderson Investors和Logos Capital也参加了会议。现有投资者包括Third Rock Ventures、ARCH Venture Partners、Matrix Capital Management、GV、General Catalyst、Andreessen Horowitz（a16z）、Foresite Capital、Woodline Partners LP、Casdin Capital、Piper Heartland Healthcare Capital、Moore Strategic Ventures以及其他现有领先的医疗保健投资者。Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量，为患有肾脏，心血管和相关代谢疾病（包括肥胖症）的患者开发新型小分子精密药物。

The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company's pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients..

该公司正在利用其Compass平台推进一条管道，该平台提供了对疾病遗传变异的见解，并将其与特定患者群体中驱动疾病的生物途径联系起来。该公司的管道由两个全资主导项目MZE829和MZE782领导，每个项目都代表了一种针对患者的新型精准医学方法。。